New hope for kids with rare seizure disorder: ION337 trial launches
NCT ID NCT07531745
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests a new medicine called ION337 in children aged 2 to 12 with Dravet syndrome, a severe form of epilepsy. The main goal is to see if the drug is safe and tolerable when given as a spinal injection. Researchers will also measure how the drug moves through the body and whether it helps reduce seizures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Le Bonheur Children's Hospital
RECRUITINGMemphis, Tennessee, 38103, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
University of Michigan Health System
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Virtual therapy helps kids with rare epilepsy gain daily living skills
- New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
- Could a repurposed drug tame seizures in adult dravet patients?
- New hope for rare epilepsy: fenfluramine made available for dravet patients
- Could a seizure drug also prevent sudden death in dravet syndrome?